Duopharma Biotech Berhad (KLSE:DPHARMA)
1.030
-0.050 (-4.63%)
At close: Nov 20, 2026
Duopharma Biotech Berhad Ratios and Metrics
Market cap in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 991 | 1,202 | 1,202 | 1,212 | 1,533 | 1,582 | |
Market Cap Growth | -18.25% | 0% | -0.79% | -20.94% | -3.10% | -33.70% |
Enterprise Value | 1,180 | 1,428 | 1,469 | 1,522 | 1,819 | 1,881 |
Last Close Price | 1.03 | 1.21 | 1.18 | 1.16 | 1.46 | 1.50 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 9.20 | 13.75 | 19.19 | 23.02 | 21.87 | 24.09 |
Forward PE | 9.18 | 12.08 | 14.74 | 14.77 | 15.91 | 20.97 |
PS Ratio | 1.08 | 1.29 | 1.48 | 1.72 | 2.20 | 2.48 |
PB Ratio | 1.24 | 1.59 | 1.70 | 1.76 | 2.34 | 2.54 |
P/TBV Ratio | 1.29 | 1.60 | 1.71 | 1.78 | 2.35 | 2.56 |
P/FCF Ratio | 12.59 | 15.03 | 20.12 | 76.43 | 301.61 | - |
P/OCF Ratio | 9.78 | 11.26 | 14.43 | 24.84 | 21.82 | 36.62 |
PEG Ratio | 0.79 | 0.61 | 0.72 | 12.31 | 1.10 | 4.11 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.29 | 1.53 | 1.81 | 2.16 | 2.61 | 2.94 |
EV/EBITDA Ratio | 5.97 | 8.35 | 10.70 | 13.35 | 14.80 | 16.36 |
EV/EBIT Ratio | 7.45 | 10.67 | 14.66 | 19.34 | 19.57 | 21.19 |
EV/FCF Ratio | 14.99 | 17.85 | 24.59 | 95.99 | 357.77 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.46 | 0.66 | 0.73 | 0.80 | 0.66 | 0.65 |
Debt / EBITDA Ratio | 1.87 | 2.84 | 3.66 | 4.67 | 3.41 | 3.41 |
Debt / FCF Ratio | 4.71 | 6.20 | 8.63 | 34.61 | 84.91 | - |
Net Debt / Equity Ratio | 0.24 | 0.27 | 0.35 | 0.41 | 0.42 | 0.43 |
Net Debt / EBITDA Ratio | 0.97 | 1.20 | 1.83 | 2.44 | 2.23 | 2.31 |
Net Debt / FCF Ratio | 2.41 | 2.57 | 4.20 | 17.55 | 53.90 | -4.02 |
Asset Turnover | 0.65 | 0.66 | 0.60 | 0.55 | 0.58 | 0.57 |
Inventory Turnover | 1.66 | 2.10 | 2.08 | 1.83 | 1.82 | 2.06 |
Quick Ratio | 2.06 | 1.66 | 2.65 | 2.59 | 1.13 | 1.18 |
Current Ratio | 3.67 | 2.60 | 4.08 | 4.06 | 2.05 | 2.15 |
Return on Equity (ROE) | 13.93% | 11.93% | 8.97% | 7.84% | 10.96% | 10.36% |
Return on Assets (ROA) | 7.61% | 6.18% | 4.60% | 4.10% | 5.88% | 5.91% |
Return on Invested Capital (ROIC) | 12.31% | 10.59% | 8.15% | 6.91% | 8.44% | 8.37% |
Return on Capital Employed (ROCE) | 13.60% | 11.80% | 8.40% | 6.70% | 9.70% | 9.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 10.87% | 7.27% | 5.21% | 4.34% | 4.57% | 4.15% |
FCF Yield | 7.95% | 6.65% | 4.97% | 1.31% | 0.33% | -4.18% |
Dividend Yield | 4.42% | 3.64% | 2.40% | 1.82% | 1.43% | 1.29% |
Payout Ratio | 40.67% | 38.49% | 42.99% | 16.81% | 11.70% | 68.45% |
Buyback Yield / Dilution | 0.01% | - | -0.36% | -1.08% | -2.15% | -0.02% |
Total Shareholder Return | 4.42% | 3.64% | 2.04% | 0.75% | -0.72% | 1.27% |